Key points are not available for this paper at this time.
Design
Editorial
Highlights a novel mutation (BLVRB S111L) linking reactive oxygen species deregulation to thrombocytosis.
In this issue of Blood, Wu et al describe a novel dominant negative loss-of-function mutation (BLVRB S111L) in a heme catabolic pathway deregulating reactive oxygen species (ROS) and associated with thrombocytosis.1
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: